KEYTRUDA® (Pembrolizumab) and KEYTRUDA QLEX® (Pembrolizumab and berahyaluronidase alfa-pmph)

The FDA on February 10, 2026, approved KEYTRUDA®, as well as KEYTRUDA QLEX® in combination with Paclitaxel, with or without Bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens. KEYTRUDA® and KEYTRUDA QLEX® are products of Merck & Co.